Merck KGaA to buy Springworks for $3.9 billion Merck KGaA (OTCPK:MKGAF) is set to acquire SpringWorks Therapeutics (SWTX) for ...

Merck KGaA is shaping up to take on Daiichi Sankyo and Ono Pharma in the market for tenosynovial giant cell tumour (TGCT) therapies after its drug candidate pimicotinib cleared a phase 3 trial.

AstraZeneca and Ionis are set fair for EU approval of Wainzua, their treatment for polyneuropathy associated with transthyretin-mediated amyloidosis (ATTR), after the EMA's human medicines ...